Neomycin

<p>Neomycin is an <a href="/facts/Aminoglycoside/eNQrtDg0">aminoglycoside</a> <a href="/facts/Antibiotic/sF1kIfxg">antibiotic</a> that displays bactericidal activity against <a href="/facts/Gram-negative/S1PbVtp4">Gram-negative</a> aerobic <a href="/facts/Bacilli/TQwde4wq">bacilli</a> and some anaerobic bacilli where resistance has not yet arisen. It is generally not effective against <a href="/facts/Gram-positive/H6WYQ17e">Gram-positive</a> bacilli and anaerobic Gram-negative bacilli. Neomycin comes in oral and topical formulations, including creams, ointments, and eyedrops. Neomycin belongs to the <a href="/facts/Aminoglycoside/eNQrtDg0">aminoglycoside</a> class of antibiotics that contain two or more <a href="/facts/Amino_sugar/AWL3WqGF">amino sugars</a> connected by <a href="/facts/Glycosidic_bond/xhYwU6sl">glycosidic bonds</a>.
</p><p>Neomycin was discovered in 1949 by microbiologist <a href="/facts/Selman_Waksman/sq4CBkQ5">Selman Waksman</a> and his student Hubert Lechevalier at <a href="/facts/Rutgers_University/dC8074a9">Rutgers University</a>.  Neomycin received approval for medical use in 1952. Rutgers University was granted the patent for neomycin in 1957.
</p>

Neomycin open-in-new

Neomycin